International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1235-1242 , 1 August 2001

Potency after permanent prostate brachytherapy for localized prostate cancer

  • Louis Potters, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Center, NY, USA
    • Corresponding Author InformationReprint requests to: Louis Potters, M.D., Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, 1000 N. Village Ave., Rockville Center, New York 11570. Tel: (516) 256-3600; Fax: (516) 256-1644
    • ,
  • Taryn Torre, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Center, NY, USA
    • ,
  • Paul A Fearn, B.A.

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Steven A Leibel, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Michael W Kattan, Ph.D.

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Received 27 December 2000 ,Revised 16 March 2001 ,Accepted 20 March 2001.

References 

  1. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  2. Kattan MW, Zelefsky M, Kupelian P, Scardino PT, Fuks Z, Leibel S. A pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000.
  3. Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 1999;5:301–306
  4. Mulcahy JJ. Erectile function after radical prostatectomy. Semin Urol Oncol. 2000;18:71–75
  5. Mantz CA, Nautiyal J, Awan A, et al.  Potency preservation following conformal radiotherapy for localized prostate cancer (Impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors). Cancer J Sci Am. 1999;5:230–236
  6. Stock RG, Kao J, Stone NN, et al.  Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. Radiother Oncol. 2000;57:315–321
  7. Fleming ID, Cooper JS, Henson DE, et al.  AJCC cancer staging manual. 5th edition. Philadelphia, Pennsylvania: Lippincott-Raven; 1997;
  8. Nath R, Anderson LL, Meli JA, Olch AJ, Stitt JA, Williamson JF. Code of practice for brachytherapy physics (Report of the AAPM Radiation Therapy Committee Task Group No. 56. American Association of Physicists in Medicine). Med Phys. 1997;24:1557–1598
  9. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Cancer Res Clin Oncol. 1958;53:457–816
  11. Cox DR, Abadir R. Regression models and life tables. J Roy Statist Soc. 1972;34:187–220
  12. DiBiase SJ, Wallner K, Tralins K, Sutlief S. Brachytherapy radiation doses to the neurovascular bundles. Int J Radiat Oncol Biol Phys. 2000;46:1301–1307
  13. Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 1996;35:267–272
  14. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;40:129–133
  15. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology. 2000;55:91–96
  16. Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 2000;163:851–857
  17. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. 2000;55:58–61
  18. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187–1192
  19. Potters L, Cha C, Ashley R, et al. The role of external beam irradiation in patients undergoing prostate brachytherapy. Urol Oncol 2000.
  20. Robinson JW, Dufour MS, Fung TS. Erectile functioning of men treated for prostate carcinoma. Cancer. 1997;79:538–544
  21. Stanford JL, Feng Z, Hamilton AS, et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer (The Prostate Cancer Outcomes Study). JAMA. 2000;283:354–360
  22. Feldman HA, Goldstein I, Hatzichristou DG. Impotence and its medical and psychosocial correlates (Results of the Massachusetts Male Aging Study). J Urol. 1994;151:54–62
  23. Pinnock CB, Stapleton AM, Marshall VR. Erectile dysfunction in the community (A prevalence study). Med J Aust. 1999;171:353–357
  24. Siegel T, Moul JW, Spevak M, Alvord WG, Constabbile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001;165:430–435
  25. Beard CJ, Propert KJ, Rieker PP, et al.  Complications after treatment with external-beam irradiation in early-stage prostate cancer patients (A prospective multiinstitutional outcomes study). J Clin Oncol. 1997;15:223–229
  26. Thompson IM, Thomp . Editorial comment J Urol. 2001;165:435
  27. Litwin MS, Flanders SC, Pasta DJ, et al.  Sexual function and bother after radical prostatectomy or radiation for prostate cancer (Multivariate quality of life analysis from CAPSURE Cancer of the Prostate Strategic Urologic Research Endeavor). Urology. 1999;54:503–508
  28. Schroder FH, Collette L, de Reijke TM, Whelan P. Prostate cancer treated by anti-androgens (Is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer). Br J Cancer. 2000;82:283–290
  29. Zelefsky MJ, Wallner KE, Ling CC, et al.  Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517–522
  30. Merrick GS, Butler WM, Lief JH, Stipetich RL, Abel LJ, Dorsey AT. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology. 1999;53:1112–1116
  31. Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology. 1999;53:775–778
  32. Fowler JE. Complications of treatment for localized prostate cancer. J Urol. 1998;160:1386

PII: S0360-3016(01)01578-4

International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1235-1242 , 1 August 2001

Article Tools

* Image Usage & Resolution